• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.

作者信息

Weber Alexander N R, Tapia-Abellán Ana, Liu Xiao, Dickhöfer Sabine, Aróstegui Juan I, Pelegrín Pablo, Welzel Tatjana, Kuemmerle-Deschner Jasmin B

机构信息

Interfaculty Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.

Clusters of Excellence EXC 2180 "Image-Guided and Functionally Instructed Tumor Therapies" and EXC 2124 "Controlling Microbes to Fight Infection", University of Tübingen, Germany.

出版信息

Rheumatology (Oxford). 2022 Oct 6;61(10):e299-e313. doi: 10.1093/rheumatology/keac273.

DOI:10.1093/rheumatology/keac273
PMID:35579347
Abstract
摘要

相似文献

1
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.MCC950/CRID3对冷吡啉相关周期性综合征（CAPS）相关突变NLRP3炎性小体的有效体外抑制作用
Rheumatology (Oxford). 2022 Oct 6;61(10):e299-e313. doi: 10.1093/rheumatology/keac273.
2
MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.MCC950/CRID3 能够强烈靶向野生型 NLRP3 的 NACHT 结构域，但不能靶向与疾病相关的突变体，从而抑制炎症小体。
PLoS Biol. 2019 Sep 16;17(9):e3000354. doi: 10.1371/journal.pbio.3000354. eCollection 2019 Sep.
3
Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.对《MCC950/CRID3对冷吡啉相关周期性综合征（CAPS）相关突变NLRP3炎性小体的有效体外抑制》的评论
Rheumatology (Oxford). 2023 May 2;62(5):e166-e167. doi: 10.1093/rheumatology/keac717.
4
Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply.对《MCC950/CRID3对冷吡啉相关周期性综合征（CAPS）相关突变NLRP3炎性小体的有效体外抑制：回复》的评论
Rheumatology (Oxford). 2023 May 2;62(5):e168-e169. doi: 10.1093/rheumatology/keac718.
5
Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants.通过疾病相关变体的功能分析阐明NLRP3激活和抑制的机制。
Nat Immunol. 2025 Mar;26(3):511-523. doi: 10.1038/s41590-025-02088-9. Epub 2025 Feb 10.
6
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.一种用于治疗炎症性疾病的NLRP3炎性小体小分子抑制剂。
Nat Med. 2015 Mar;21(3):248-55. doi: 10.1038/nm.3806. Epub 2015 Feb 16.
7
4-octyl itaconate reduces human NLRP3 inflammasome constitutive activation with the cryopyrin-associated periodic syndrome p.R262W, p.D305N and p.T350M variants.衣康酸4-辛酯可降低与冷吡啉相关周期性综合征的p.R262W、p.D305N和p.T350M变体相关的人类NLRP3炎性小体的组成性激活。
Cell Mol Life Sci. 2025 May 23;82(1):209. doi: 10.1007/s00018-025-05699-5.
8
MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.MCC950治疗NLRP3介导的炎症性疾病：最新证据与治疗结果
Int Immunopharmacol. 2022 May;106:108595. doi: 10.1016/j.intimp.2022.108595. Epub 2022 Feb 3.
9
NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.NLRP3 炎性小体与 NLRP3 相关自身炎症性疾病：从 cryopyrin 的功能到靶向治疗。
Front Immunol. 2022 Oct 6;13:1007705. doi: 10.3389/fimmu.2022.1007705. eCollection 2022.
10
Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.MCC950 通过抑制 IL-1β 和胰岛细胞死亡来抑制 NLRP3 炎性体，从而改善胰岛移植的代谢结局。
Sci Rep. 2020 Oct 21;10(1):17920. doi: 10.1038/s41598-020-74786-3.

引用本文的文献

1
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets.NLRP3炎性小体从周期性发热到治疗靶点的作用扩展
Nat Immunol. 2025 Aug 18. doi: 10.1038/s41590-025-02230-7.
2
4-octyl itaconate reduces human NLRP3 inflammasome constitutive activation with the cryopyrin-associated periodic syndrome p.R262W, p.D305N and p.T350M variants.衣康酸4-辛酯可降低与冷吡啉相关周期性综合征的p.R262W、p.D305N和p.T350M变体相关的人类NLRP3炎性小体的组成性激活。
Cell Mol Life Sci. 2025 May 23;82(1):209. doi: 10.1007/s00018-025-05699-5.
3
Functional analysis of NLRP3 variants provides insight into inflammasome regulation.
NLRP3变异体的功能分析为炎性小体调控提供了深入见解。
Nat Immunol. 2025 Mar;26(3):337-339. doi: 10.1038/s41590-025-02093-y.
4
Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants.通过疾病相关变体的功能分析阐明NLRP3激活和抑制的机制。
Nat Immunol. 2025 Mar;26(3):511-523. doi: 10.1038/s41590-025-02088-9. Epub 2025 Feb 10.
5
Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.从细胞表型筛选到临床候选药物的探索：NLRP3炎性小体的选择性靶向作用
EMBO Mol Med. 2025 Jan;17(1):54-84. doi: 10.1038/s44321-024-00181-4. Epub 2024 Dec 9.
6
Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.与 CAPS 自身炎症相关的 NLRP3 功能获得性突变体的功能多样性。
J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20231200. Epub 2024 Mar 26.
7
Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency.新型 NLRP3 抑制剂化学型，针对 CRID3 结合口袋具有高活性。
Life Sci Alliance. 2024 Mar 22;7(6). doi: 10.26508/lsa.202402644. Print 2024 Jun.
8
Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production.致病性 NLRP3 突变体形成组成性激活的炎症小体，导致 IL-1β 产生的免疫代谢限制。
Nat Commun. 2024 Feb 6;15(1):1096. doi: 10.1038/s41467-024-44990-0.
9
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.NLRP3 炎性小体激活和 KRAS 突变性 CMML 患者的症状负担可被 IL-1 阻断治疗逆转。
Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329.
10
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets.靶向NLRP3炎性小体：从信号传导机制到治疗靶点
Nat Rev Drug Discov. 2024 Jan;23(1):43-66. doi: 10.1038/s41573-023-00822-2. Epub 2023 Nov 29.